Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 1999

View Archived Issues

Ilex Oncology updates investors at healthcare conference

Helix BioPharma finalizes acquisition of PharmaDerm

Photogen Technologies and Elan form joint venture for lymph node cancer diagnostic

Merck's license to nonviral gene delivery technology extended to therapeutic vaccines

Incara begins clinical program for IBD, explores strategic alternatives

Merger update: Warner-Lambert, AHP intend to stick with original agreement

Advisory committee supports approval of Prevenar

Vasopressin antagonist VPA-985: summary of clinical data presented at ASN

Abbott enters diabetes collaboration with Karo Bio

Amgen presents promising phase III results for NESP at ASN

Selectin ligand antagonist TBC-1269 attenuates renal ischemic reperfusion injury in rats

New serotonergic agents for depression and related disorders in development at AHP

Neurogen patents new CRF antagonists

European patents cover novel tricyclic sPLA2 inhibitors designed at Lilly

Texas Biotechnology presents integrin antagonists for alphavbeta1-mediated diseases

Water-soluble prodrugs of NK1 receptor antagonists from Warner-Lambert

Pfizer discovers new compounds that inhibit MMPs and other related enzymes

BioTime files for Canadian regulatory approval of Hextend

Banyu presents preclinical pharmacokinetic, metabolic data for J-107088 at recent scientific meeting

Stockholders approve Cypros/RiboGene merger

AGI-1067 prevents the progression of atherosclerosis independent of its effects on cholesterol

Combination tirapazamine, cisplatin and radiotherapy highly effective in advanced H&N cancer

News from AHA: novel MMP inhibitor from P&U effective in CHF model in rats

Initial phase II results point to safety and potential efficacy of RSR-13 in GBM

Soluble CD39: novel antiplatelet agent enters the pipeline at Immunex

Levosimendan NDA withdrawn for amendment and subsequent refiling

Amylin successfully completes pivotal trials of Symlin; filings scheduled for mid-2000

P-selectin blocker SKK-60037 may help prevent progressive renal injuries

ASN presentation for VNA-932, a potent and selective, nonpeptide V2 agonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.